12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Company News  |  Other News

GlaxoSmithKline cancer news

A patent invalidation by India's Intellectual Property Appellate Board (IPAB) means GlaxoSmithKline will lose exclusivity for breast cancer drug Tykerb lapatinib in India in January 2019, more than two years sooner than expected. IPAB revoked a GSK patent that was set to expire in June 2021, citing obviousness. The patent covered the salt form of lapatinib. IPAB upheld a second...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >